Member Info for Schlum

An announcement of a roll over or extension of the loan, would more than likely see a substantial rise in the SP.

Substantial cash realisations from the portfolio of AI companies, continue to be expected over the next two quarters.

The increasing partnership with the US national cancer research institute, is an extraordinary achievement for a company the size of FAB. This alone verifies the capability of FAB’s scientific research pedigree. Royalties from any joint venture product successes,would of course be transformative for AIM listedFAB.

Very interesting article.

CA selling?

Positive!

With so many irons in the fire, Apta must be close to closing on the first of many.

The SP is at a 71% discount to current NAV, and the AGM statement reported that exciting further realisations are expected to be announced shortly.

On that basis the risk/reward looks highly favourable.

….launched a comprehensive Security solution for Chat GPT Open AI….which is powered by GetVisibility ( one of Mindflair’s largest investments).

Further realisations from venture fund are expected shortly….!

No news… really!

At a 70% discount to NAV today…. the SP most certainly could easily double if not more. Any news re IPOs or further realisations and ….pick your number!

Hoping for a clear update on our AI portfolio companies. Any news on further realisations , particularly re GetVisibility will be well received.

N4P is now on an exciting trajectory after many years of research.

The risk versus reward of owning a slice of this company ,has never looked more attractive.

An optimist might suggest the company will prosper from here out, assuming the US customer resumes production.

The revenues from RF’s new customers is meaningful and home composting plastics is the future.

RF division in major turnaround . Bioplastics, more uncertainty short term, but home composting products in 2025 will probably see good take up.

Management must be seen to be able to deliver positive cash flow soon.

Biome may yet survive,just.

AGM in London next Friday 27th Sept..

It seems the eminent Dr Palfreyman is to hit the ground running.

As he says, N4P is at an exciting stage, its unique delivery systems will be very attractive in enhancing the effect of many existing, pharmaceutical therapeutics.

The news we have been waiting for. Congratulations. N4P may be on the cusp of finally seeing meaningful reward for its scientific endeavours.

It would be positive indeed, if Fusion negotiate royalty percentages on the client company’s already valuable commercial protein assets.

Very encouraging presentation. I was particularly taken by Adrian’s excitement in describing the potential opportunities he sees in the work to date,utilising the Mammalian display part of the Optimal library, to significantly increase commercial protein asset expression by up to 30x.

I do not pretend to understand the science, but improving the effectiveness of clients commercial assets , to this degree, clearly is giving Adrian excitement as to the future rewards for Fusion.

At £2m market cap N4P offers tremendous upside.

Today at 3pm.

There remains a distinct possibility of an update on realising the valuation within Get Visibility. That would put a rocket under the SP.. All is possible.